Condition · ICD-11 8A40
Multiple sclerosis spasticity
Reviewed by Dr. Placeholder D (HPCSA MP0XXXXX · Neurology) · Last updated · Published
Spasticity — involuntary muscle stiffness and spasm — is among the most disabling symptoms of multiple sclerosis. Conventional first-line pharmacotherapy includes baclofen, tizanidine, and gabapentin, often combined with physiotherapy. Cannabinoid-based therapy, particularly a 1:1 THC:CBD oromucosal formulation, has an established evidence base for MS-related spasticity and is considered when conventional agents have been inadequately effective or poorly tolerated. South African access is via Section 21, coordinated with the patient’s treating neurologist.
What the evidence says
A 1:1 THC:CBD oromucosal spray is approved in several jurisdictions (UK, Germany, Canada) for MS spasticity after inadequate response to first-line antispasmodics. Multiple randomised controlled trials have shown statistically significant improvements in patient-reported spasticity scales, though clinician-rated scales show smaller effects. The EAN (European Academy of Neurology) guideline recommends cannabinoids for refractory MS spasticity as a second-line option. SA pathway is per-patient under Section 21.
How the doctor will evaluate you
The consulting doctor will require your treating neurologist’s most recent letter, MRI summary if available, a current list of antispasmodic medications with dose and duration, and your physiotherapy notes. A spasticity self-assessment (NRS 0–10) is usually requested over a 1–2 week baseline. The doctor liaises with your neurologist before submitting the Section 21 application — this is not a replacement for your existing MS care.
When to see a doctor urgently
- Active relapse requiring acute neurology review
- Cognitive symptoms that may be worsened by THC
- Polypharmacy with CYP450 substrates (see drug-interaction considerations)
- History of psychosis
If any of the above apply, seek in-person medical care — do not wait for a remote Section 21 consultation.
The South African Section 21 pathway
MS spasticity is one of the strongest-evidenced indications in the South African Section 21 cannabis pathway. Applications are typically supported by the neurologist’s correspondence and a documented trial of first-line antispasmodics. Authorisation is per-product and time-limited; renewals require continued clinical justification.
Frequently asked
- Does cannabinoid therapy slow MS progression?
- No. The evidence supports symptomatic relief of spasticity — not disease modification. Disease-modifying therapy remains the domain of your neurologist.
- Can I take this alongside my current antispasmodics?
- Often yes, but dose review is essential. The doctor may gradually adjust baclofen or tizanidine doses depending on your response, and will watch for additive sedation.
- Will this affect my ability to drive?
- THC-containing formulations can cause impairment, particularly during dose-titration. The doctor will discuss driving restrictions and recommend abstaining from driving while doses are being adjusted.
Related conditions
Think this might apply to you? An HPCSA-registered doctor will review your case.
START ELIGIBILITY REVIEWR500 consultation · R400 SAHPRA fee per product · 3–7 days end-to-end